Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

'Sleep disruption is so much more than the inconvenience of being able to sleep at the desired time - it is a global health disruption', said Russell Foster, Professor of Circadian Neuroscience at the University of Oxford, speaking at Wired Health in London on 6 May.

He explained how our increased understanding of the neuroscience of sleep has informed understanding of both ophthalmology and mental health. Read more from Wired...

At the same event, the insomnia app Sleepio won the startup competition. One of the senior researchers in the Nuffield Department of Clinical Neurosciences, Professor Colin Espie, co-founded Sleepio with Peter Hames. Read more on the Sleepio blog...

Similar stories

New insights into the effect of exposure to dim light in the evening on the biology of the sleep-wake cycle

A new study has revealed more about how exposure to dim light in the evening affects circadian health. The findings emphasise the need to optimise our artificial light exposure if we are to avoid shifting our biological clocks.

Blood lipoprotein levels linked to future risk of amyotrophic lateral sclerosis

Greater understanding of the role of lipoproteins could support screening and efforts to develop treatments.

International study finds insomnia, anxiety and depression very prevalent during first phase of COVID-19 pandemic

Researchers are recommending public health interventions to reduce the long-term adverse outcomes associated with chronic insomnia and mental health problems.

Alexander Davies wins top UKRI Future Leaders Fellowship

Alex is one of eight Oxford University academics who have been awarded significant financial funding from the UKRI Future Leaders Fellowships Scheme

New study on link between autoimmunity and pain

Patients with autoantibodies which target neuronal proteins can have pain as an under-recognised clinical manifestation.